RecruitingPHASE1, PHASE2NCT06157541

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

Studying Astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Queensland Institute of Medical Research
Principal Investigator
Rajiv Khanna, PhD
QIMR Berghofer Medical Research Institute
Intervention
Allogeneic cytomegalovirus-specific T cells(biological)
Enrollment
58 target
Eligibility
18 years · All sexes
Timeline
20242028

Study locations (4)

Collaborators

CUREator · Merck Sharp & Dohme LLC · The Newro Foundation · Royal Brisbane and Women's Hospital · Princess Alexandra Hospital, Brisbane, Australia · Austin Hospital, Melbourne Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06157541 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma

← Back to all trials